Macular Degeneration Treatment Market (Disease Indication: Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, and Others) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Macular Degeneration Treatment market size was estimated at USD 9.10 billion in 2021 and is expected to surpass around USD 21.50 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.30% during the forecast period 2022 to 2030.

Treatment innovations for macular degeneration are providing hope that the disease could be cured one day. Promising treatments are dependent on the stage of disease progression. Nutritional therapy can help in dry macular degeneration treatment during the early stage of the disease. It includes a healthy diet that is high in antioxidants to support the cells of the macula. If macular degeneration is advanced but still dry, supplements to increase the number of certain vitamins and minerals that could increase healthy pigments and support cell structure are prescribed. Each affected eye is assigned to either laser treatment or observation at random. Laser treatment reduces the risk of severe visual loss in eligible eyes with CNV in extrafoveal, juxtafoveal, and subfoveal locations.

Report Scope of the Macular Degeneration Treatment Market

 Technological Advancements and Promising Pipeline Products to Drive Global Market

Rise in prevalence of age-related macular degeneration (AMD) is primarily expected to propel the global macular degeneration treatment market in the next few years. Increase in healthcare spending and rise in patient awareness are also likely to fuel the global market during the forecast period. Launch of novel products for the treatment of geographic atrophy, late stage of dry age-related macular degeneration treatment (dAMD), and wet AMD (wAMD) are projected to augment the age-related macular degeneration market. Drugs such as Apellis’ APL-2, Ophthotech’s Zimura, and Novartis’ brolucizumab, a longer-acting anti-VEGF, are anticipated to drive the global macular degeneration treatment market size in the near future. In particular, the launch of drugs in the AMD market to treat dAMD is anticipated to be a major driver, as currently, no prescription medications are available for this condition.

High Cost of Patented Drugs Restraining Global Market

Patent expiry is likely to pose a threat to the market players' expansion strategies. On the other hand, exorbitant pricing may not be a good strategy to adopt for players who hold patents for their drugs. For instance, the patent for Lucentis expired in the U.S. in 2020, while its European patent expired in July 2022. Several companies are in the race to introduce Lucentis biosimilar for the monthly treatment of neovascular age-related macular degeneration treatment (nAMD). Lack of prescription drugs in the international AMD market is expected to hamper demand in the near future.

Increase in Number of Treatments Fueling Wet AMD Segment

In terms of disease indication, the global maculation degeneration market has been bifurcated into wet age-related macular degeneration and dry age-related macular degeneration. The wet age-related macular degeneration segment accounted for major share of the global market in 2021. Wet AMD is treated with intravitreal injections (IVT), with an estimated 22.3 million procedures performed globally in 2017. Around 75% of anti-VEGF injections were given to treat wet AMD. High prevalence of the condition, branded medications, growth in awareness, and increase in the number of treatments for wet AMD contributed to the segment's dominant market share.

Large Patient Population Driving Anti-vascular Endothelial Growth Factors Segment

Based on drug class, the global macular degeneration treatment market has been bifurcated into anti-vascular endothelial growth factors and others. Blinding retinal conditions, such as diabetic macular edoema (DME), age-related macular degeneration (AMD), and retinal diseases, are largely attributed to the pathogenesis of vascular endothelial growth factor (VEGF). It has been demonstrated that inhibiting VEGF activity within the eye can improve and restore visual function in AMD patients. Direct macular degeneration injections of anti-VEGF medications are made into the eye's vitreous cavity. Large patient pool across the globe is another factor likely to propel the anti-vascular endothelial growth factors segment in the near future.

Majority of New AMD Cases in Developed Countries Treated in Hospitals

In terms of distribution channel, the global macular degeneration treatment market has been divided into hospitals, ophthalmology clinics, and ambulatory surgical centers. The hospitals segment is expected to account for more than 52.6% share of the global market by 2030. The segment is likely to grow at a CAGR of 7.0% during the forecast period. Hospitals treat the majority of new AMD cases in developed countries.

Regional Outlook of Global Macular Degeneration Treatment Market

North America accounted for the largest global macular degeneration treatment market share in 2021. The trend is projected to continue during the forecast period. Adoption rate of prescription AMD drugs is high in the U.S., and the number of new drug approvals in the country is increasing.

Europe accounted for more than 32.9% share of the global macular degeneration treatment market in 2021. The macular degeneration treatment market in the region is expected to grow at a rapid pace during the forecast period due to large unmet needs and increase in purchasing power to obtain branded drugs. Improvement in lifestyle, particularly among the urban population, and the introduction of new drugs for macular degeneration are expected to boost the demand for macular degeneration treatment drugs in Europe.

Asia Pacific accounted for more than 13.4% share of the global market in 2021 due to large population base and increase in treatment adoption rate in the region. Rise in disposable income and health awareness have increased the diagnosis and treatment rates. This has resulted in a rise in number of macular degeneration drugs in the market. Key players are investing significantly to establish themselves in Asia Pacific. This is expected to augment the market in the region.

Analysis of Key Players in Global Macular Degeneration Treatment Market

The global macular degeneration treatment market is fragmented, with the presence of a vast number of large-scale players. Key players operating in the global macular degeneration treatment market include AbbVie, Inc., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Novartis AG, and Santen Pharmaceutical Co., Ltd. These players are adopting growth strategies such as new product development, product launches, agreements, partnerships, and mergers.

Key Developments in Global Macular Degeneration Treatment Market

• In August 2022, the Philippine FDA approved Novartis' brolucizumab for the treatment of neovascular (wet) age-related macular degeneration (AMD)
• In June 2022, Health Canada had approved Roche's VABYSMO (faricimab injection) for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
• In February 2022, Regeneron presented positive phase 2 results for high dose 8 mg AFLIBERCEPT in wet age-related macular degeneration at angiogenesis meeting

Some of the prominent players in the Macular Degeneration Treatment Market include:

• Pfizer, Inc.
• AbbVie, Inc.
• F. Hoffmann-La Roche, Ltd.
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Novartis AG
• Santen Pharmaceutical Co., Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Macular Degeneration Treatment market

• Disease Indication
• Wet Age-related Macular Degeneration
• Dry Age-related Macular Degeneration
• Others
• Drug Class
• Anti-vascular Endothelial Growth Factor
• Others
• Distribution Channel
• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Macular Degeneration Treatment industry analysis from 2022 to 2030 to identify the prevailing Macular Degeneration Treatment industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Macular Degeneration Treatment industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Macular Degeneration Treatment industry trends, key players, market segments, application areas, and market growth strategies.